Volume 7.23 | Jun 18

Cord Blood News 7.23 June 18, 2015
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  CBN on Twitter
Enhancing Hematopoietic Stem Cell Transplantation Efficacy by Mitigating Oxygen Shock
By collecting and manipulating bone marrow and cord blood in native conditions of hypoxia, scientists demonstrated that brief exposure to ambient oxygen decreased recovery of long-term repopulating hematopoietic stem cells and increases progenitor cells, a phenomenon they term extraphysiologic oxygen shock/stress. [Cell] Abstract | Graphical Abstract
It all starts with the right cells! Order fresh and frozen primary cells now.
PUBLICATIONS (Ranked by impact factor of the journal)
High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation with Reduced-Intensity Conditioning
Researchers evaluated associations between graft T-cell doses and outcomes in 200 patients who underwent reduced-intensity conditioned allogeneic hematopoietic stem-cell transplantation with a peripheral blood stem-cell graft. [J Clin Oncol] Abstract

Treatment with Agonistic DR3 Antibody Results in Expansion of Donor Tregs and Reduced Graft-Versus-Host Disease
The authors investigated whether treating donor mice with a single dose of agonistic antibody to DR3 could alleviate acute graft versus host disease in a MHC-mismatched bone marrow transplantation model. [Blood] Abstract

Treprostinil Indirectly Regulates Endothelial Colony Forming Cell Angiogenic Properties by Increasing VEGF-A Produced by Mesenchymal Stem Cells
Researchers examined the effect of treprostinil on endothelial colony forming cells (ECFC) obtained from cord blood in terms of colony numbers, proliferative and clonogenic properties in vitro, as well as in vivo vasculogenic properties. Treprostinil inhibited viability of cultured ECFC but did not modify their clonogenic properties or the endothelial differentiation potential from cord blood stem cells. [Thromb Haemost]
Abstract | Full Article

The Impact of Repeated Autologous Infusion of Hematopoietic Stem Cells in Patients with Liver Insufficiency
Investigators assessed the clinical and biochemical effects of repeated stem cell infusion. Ninety patients with liver cirrhosis were randomized to receive either one session treatment or two sessions four months apart of autologous hematopoietic stem cells transplantation and a control group who received regular liver treatment. [Stem Cell Res Ther] Abstract | Full Article

Retinal Angiogenesis Effects of TGF-β1, and Paracrine Factors Secreted from Human Placental Stem Cells in Response to a Pathological Environment
Investigators evaluated the role of systemically injected human placental amniotic membrane-derived mesenchymal stem cells (AMSCs) on pathological neovascularization of proliferative retinopathy. They determined that AMSCs secreted higher levels of transforming growth factor beta (TGF-β1) than other mesenchymal stem cells and the secreted TGF-β1 directly suppressed the proliferation of endothelial cells under pathological conditions in vitro. [Cell Transplant] Abstract

Comparative Characterization of Cells from the Various Compartments of the Human Umbilical Cord Shows that the Wharton’s Jelly Compartment Provides the Best Source of Clinically Utilizable Mesenchymal Stem Cells
The authors compared the histology, fresh and cultured cell numbers, morphology, proliferation, viability, stemness characteristics and differentiation potential of cells from the amnion, subamnion, perivascular, Wharton’s jelly, and mixed cord of five umbilical cords. [PLoS One] Full Article

In Vivo Tracking of Human Placenta Derived Mesenchymal Stem Cells in Nude Mice via (14)C-TdR Labeling
Researchers investigated the bio-distribution of human placental deciduas basalis derived mesenchymal stem cells in nude mice after intravenous injection by carbon radioisotope labeling thymidine ((14)C-TdR). [BMC Biotechnol] Abstract

Only One of These Antibodies Will Work for Your Cell Analysis. We Take the Guesswork Out of Finding the Right
Human Umbilical Cord Mesenchymal Stem Cells: An Overview of Their Potential in Cell-Based Therapy
The authors review the development of stem cell-based therapy, the manufacturing and banking process of human umbilical cord mesenchymal stem cells (HUC-MSCs), the emerging clinical studies in the field of cancer, central nervous system diseases, liver diseases and graft-versus-host disease, the potential therapeutic mechanisms, as well as challenges of HUC-MSCs in clinical translation. [Expert Opin Biol Ther] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.
Cord Blood Registry’s New Disease Registry Brings Data and Families Together to Advance Stem Cell Research
Cord Blood Registry® announced the launch of CBR’s Family Health Registry, a unique registry designed to offer insight into common diseases and conditions affecting families and to bring patients, healthcare professionals and researchers together to expedite and facilitate research related to the discovery of stem cell treatments and potential cures. [Cord Blood Registry®] Press Release

Connecticut Innovations’ Regenerative Medicine Research Fund Awards $11 Million for Scientific Research
BioInnovation Connecticut announced that the Regenerative Medicine Research Fund has awarded $11 million to scientists who are conducting biomedical, embryonic or human adult stem cell research. [Mayo Clinic] Press Release

From our sponsor:
Discover how to reduce variability in primary neuron cultures with NeuroCult™ SM.
Watch the webinar.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 57th ASH Annual Meeting & Exposition
December 5-8, 2015
Orlando, United States

Visit our events page to see a complete list of events in the cord blood community.
NEW Postdoctoral Research Scientist – Hematopoietic Stem Cell Self-Renewal and Differentiation (University of Oxford)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Hematopoietic Stem Cell Biology (Harvard Medical School)

Assistant/Associate Professor – Hematologic Malignancies (MD Anderson Cancer Center)

Postdoctoral Fellow – Immune Reconstitution in Hematopoietic Stem Cell Transplantation (Stanford University)

Postdoctoral Scientist – Hematopoietic Stem Cell Transplantation (Indiana University)

Postdoctoral Position – Epigenetic Regulation of Hematopoiesis and Leukemia (Karolinska Institutet)

Research Associate – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)

Postdoctoral Researcher – Hematopoietic Stem Cell Physiology and Pathophysiology (International Research Center for Medical Sciences)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us